- Article
Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial
- Renaud Sabatier,
- Jean-Yves Pierga,
- Hervé Curé,
- Rakan Abulnaja,
- Eric Lambaudie,
- François-Clément Bidard,
- Jean-Marc Extra,
- Patrick Sfumato and
- Anthony Gonçalves
The phase II AVASTEM trial explored the impact of chemotherapy-bevacizumab combination on breast cancer stem cells in the neoadjuvant setting. We aimed to identify biological features associated with preoperative chemotherapy efficacy and prognosis b...

